Subscribe to RSS
Xanthoma disseminatum with extensive respiratory involvement effectively treated with cladribine: a case report
Subject Editor: Financial support and sponsorship Nil.
Xanthoma disseminatum (XD) is a rare and benign proliferative systemic disease that usually affects the skin and mucosal membranes with variable extent. Extensive systemic involvement can be associated with higher morbidity. There is paucity in the literature describing this rare pathological entity, and the ideal management remains controversial. In this article, we report our experience with cladribine in treating a case of XD. We documented the clinical and pathological manifestations of a 24-year-old woman who was initially diagnosed with rheumatoid arthritis. She presented to our institute with respiratory compromise and was found to have XD affecting skin, mucosal membranes, joints, and bone marrow. The patient received six cycles of cladribine for 6 months, during which she showed a remarkable response in relation to the respiratory lesions. Her hemoglobin also normalized and inflammatory markers gradually decreased to reach normal values. However, her skin lesions did not respond to treatment but no new lesions appeared. With our experience with cladribine, we believe that it could be a promising treatment option for XD. However, more work has to be conducted to determine the efficacy and safety in the long term.
Key message: Given the rarity of this understudied entity, the natural history and the ultimate treatment remain unclear. We highlight the natural history and clinical course of xanthoma disseminatum (XD) in this article. We also describe our experience with cladribine in treating XD. We believe that similar experiences should be compiled to better understand this pathology and the effective therapy options for these patients.
Article published online:
04 August 2021
© 2020. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Oka M, Oniki S, Komatsu M, Ikeda T, Matsuo M, Miyamoto Y. et al. Xanthoma disseminatum with intracranial involvement: Case report and literature review. Int J Dermatol 2010; 49: 193-9
- 2 Montgomery H, Osterberg AE. Xanthomatosis: Correlation of clinical, histopathologic and chemical studies of cutaneous xanthoma. Arch Derm Syphilol 1938; 37: 373-402
- 3 Büyükavci M, Selimoglu A, Yildirim U, Ertekin V, Atasoy M. Xanthoma disseminatum with hepatic involvement in a child. Pediatr Dermatol 2005; 22: 550-3
- 4 Behera B, Malathi M, Thappa DM, Vamanshankar H, Parida PK, Gochhait D. Xanthoma disseminatum presenting with hoarseness. Iran J Otorhinolaryngol 2017; 29: 365-8
- 5 Campero M, Campero S, Guerrero J, Aouba A, Castro A. Cerebral and cutaneous involvements of xanthoma disseminatum successfully treated with an interleukin-1 receptor antagonist: A case report and minireview. Dermatology 2016; 232: 171-6
- 6 Gupta P, Khandpur S, Vedi K, Singh MK, Walia R. Xanthoma disseminatum associated with inflammatory arthritis and synovitis—A rare association. Pediatr Dermatol 2015; 32: e1-4
- 7 Caputo R, Veraldi S, Grimalt R, Gianotti R, Tosti A, Varotti C. et al. The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature. Dermatology 1995; 190: 19-24
- 8 Ozçelik U, Doğru D, Akçören Z, Coşkun T, Kaya S, Göçmen A. Xanthoma disseminatum: A child with respiratory system involvement and bronchiectasis. Pediatr Pulmonol 2005; 39: 84-7
- 9 Weiss N, Keller C. Xanthoma disseminatum: A rare normolipemic xanthomatosis. Clin Investig 1993; 71: 233-8
- 10 Adışen E, Aladağ P, Özlem E, Gürer MA. Cladribine is a promising therapy for xanthoma disseminatum. Clin Exp Dermatol 2017; 42: 717-9
- 11 Khezri F, Gibson LE, Tefferi A. Xanthoma disseminatum: Effective therapy with 2-chlorodeoxyadenosine in a case series. Arch Dermatol 2011; 147: 459-64